This update is a clinical signal calibration note. Ainos reported interim results from an ongoing open-label, multi-dose study of VELDONA® (low-dose oral interferon alpha) in Feline Chronic Gingivostomatitis (FCGS). The interim cut covers 6 treated cats out of 12 planned, across two dose cohorts, dosed orally three times per week for six weeks, with follow-up reported through Week 14.
The point of this report is not to oversell early data. It is to translate company-reported outcomes into a disciplined “what can we actually infer?” framework. The update explains why this readout matters: it is the first quantified snapshot of how VELDONA is performing in FCGS, linking measured inflammation scoring to tolerability in a real-world veterinary setting—useful as an evidence point, but not decisive because of the interim, open-label design and small sample size.
The report summarizes the company’s primary disease activity framework (SDAI) and then focuses on the most concrete interim observations the company disclosed:
- On local oral inflammation, 6/6 cats showed lower scores at Week 6 versus baseline, with mean improvement reported at ~38% at Week 6 and ~45% at Week 14, and a company-cited Wilcoxon signed-rank p < 0.05.
- The dashboard view also highlights that 66.7% achieved at least 30% improvement (company-reported), and it flags the evidence level explicitly (interim; open-label; n=6/12; dental procedures in 5/6 subjects).
- On safety/tolerability, the company reports stable routine labs through Week 6 and no dose-related toxicity trend in the interim set.
Crucially, the update puts this in the correct portfolio context for Ainos: in the initiating coverage, VASRO framed Ainos as two engines with two timelines, with AI Nose as the near-term execution focus and VELDONA as longer-dated optionality. Within that structure, FCGS sits as a secondary/exploratory lane—worth monitoring, but not the core commercialization driver.